Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00984867 · ClinicalTrials.gov registry record · Phase 3
Dapagliflozin DPPIV Inhibitor add-on Study
A Phase 3 study of Type 2 Diabetes, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 833
- Enrollment target
- 20
- Study locations
NCT00984867 is a Phase 3 study of Type 2 Diabetes that has completed, run by AstraZeneca. The registered enrollment target is 833 participants, below the 1,100-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00984867, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 833 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The effect of dapagliflozin on weight and blood pressure will also be studied.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Chula Vista
- Research Site - Greenbrae
- Research Site - Laguna Hills
- Research Site - Los Angeles
- Research Site - Riverside
- Research Site - West Hills
Florida
- Research Site - Boca Raton
- Research Site - DeLand
- Research Site - Jacksonville
- Research Site - Longwood
- Research Site - Miami
- Research Site - Port Orange
- Research Site - West Palm Beach
Alabama
- Research Site - Huntsville
- Research Site - Ozark
Georgia
- Research Site - Stone Mountain
Kansas
- Research Site - Wichita
Louisiana
- Research Site - Lake Charles
Minnesota
- Research Site - Edina
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 833 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00984867
The ClinicalTrials.gov registry entry for NCT00984867 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 833 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,100-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (24% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00984867 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00984867 about?
NCT00984867 is a clinical study titled "Dapagliflozin DPPIV Inhibitor add-on Study". This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The effect of dapagliflozin on weight and blood pressure will also be studied.
What is the current status of trial NCT00984867?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 833 participants. The study started on 2009-10. Estimated completion is 2011-09.
What conditions does trial NCT00984867 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00984867?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT00984867?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00984867 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.